Benefits and risks of hosting animal cells in the human brain

Nature Medicine

Volumn 3, Issue 9, 1997, Pages 964-969

  Isacson, Ole ^a,b,c   Breakefield, Xandra O ^b,c  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; BRAIN TUMOR; CELL TRANSPLANTATION; FETUS CELL; FIBROBLAST; GRAFT SURVIVAL; HUMAN; HUMAN CELL; MOUSE; NERVE DEGENERATION; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SWINE; XENOTRANSPLANTATION;

ANIMALS; BRAIN NEOPLASMS; BRAIN TISSUE TRANSPLANTATION; CLINICAL TRIALS; FETAL TISSUE TRANSPLANTATION; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; PARKINSON DISEASE; RETROVIRIDAE; RISK FACTORS; SWINE; THYMIDINE KINASE; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; SUS SCROFA; UNIDENTIFIED RETROVIRUS;

EID: 0030866841     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0997-964     Document Type: Review

References (77)

1. Patience, C., Takeuchi, Y. & Weiss, R.A. Infection of human cells by an endogenous retrovirus of pigs. Nature Med. 3, 282-286 (1997).
2. Short, M.P. et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27, 427-439 (1990).
3. Culver, K.W. et al. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256, 1550-1552 (1992).
4. Blaese, R.M. et al. In situ delivery of suicide genes in cancer therapy. XIIIth Europ. Assoc. Cancer Research Meeting. Berlin, Germany (1994).
5. Björklund, A. Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr. Opin. Neurobiol. 2, 683-689 (1992).
6. Wenning, G.K. et al. Short-and long-term survival and function of unilateral striatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 42, 95-107 (1997).
7. Kordower, J.H. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332, 1118-1124 (1995).
8. Philpott, L.M. et al. Neuropsychological functioning: following fetal striatal transplantation in Huntington's Chorea: three case presentations. Cell Transpl. 6, 203-212 (1996).
9. Deacon, T. et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nature Med. 3, 350-353 (1997).
10. Quinn, N. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog. Brain Res. 82, 619-625 (1990).
11. Pakkenberg, B., Moller, A., Gundersen, H.J., Mauritzen-Dam, A. & Pakkenberg, H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiat. 54, 30-33 (1991).
12. Guttman, M. et al. (C-11)RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease - implications for the symptomatic threshold. Neurology 48, 1578-1583 (1997).
13. Birkmayer & Hornykiewicz, O. Wien Klin. Wochenschr. 73, 787-788 (1961).
14. Bravi, D. et al. Wearing-off fluctuations in Parkinson's disease. Ann. Neurol. 36, 27-31 (1994).
15. Marsden, C.D. Problems with long-term levodopa therapyfor Parkinson's disease. Clin. Neuropharmacol. 17 (Suppl 2), S32-S44 (1994).
16. Benabid, A.L., Pollak, P., Louveau, A., Henry, S. & De Rougement, J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl. Neurophysiol. 50, 344-346 (1987).
17. Iacono, R.P. et al. The results, indications, and physiology of posteroventral pallidotomy for patients with Parkinson's disease. Neurosurgery 36, 1118-1124 (1995).
18. Benabid, A.L., Pollak, P., Hoffmann, D., Le Bas, J.F. & Gao, D.M. Chronic high-frequency thalamic stimulation in Parkinson's disease. In Therapy of Parkinson's disease, Second Ed. (eds. Koller, W.C., Paulson, C.) 381-402 (Marcel Dekker Inc., New York, 1995).
19. Widner, H. et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 1556-1563 (1992).
20. Nagatsu, T. & Ichinose, H. GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism. Neurochem. Res. 21, 245-250 (1996).
21. Tarn, S.Y. & Roth, R.H. Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Biochem. Pharmacol. 53, 441-453 (1997).
22. Hurtig, H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp. Neurol. 144, 10-16 (1997).
23. Fisher, L.J., Jinnah, H.A., Kale, L.C., Higgins, G.A. & Gage, F.H. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371-380 (1991).
24. Strecker, R.E. et al. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 22, 169-178 (1987).
25. Pakzaban, P. & Isacson, O. Neural xenotransplantation: reconstruction of neuronal circuitry across species barriers. Neuroscience 62, 989-1001 (1994).
26. Klassen, H. & Lund, R.D. Anatomical and behavioral correlates of a xenograft-mediated pupillary reflex. Exp. Neurol. 102, 102-8 (1988).
27. Klassen, H. & Lund, R.D. Parameters of retinal graft-mediated responses are related to underlying target innervation. Brain Res. 533, 181-91 (1990).
28. Honey, C.R., Charlton, H.M. & Wood, K.J. Rat brain xenografts reverse hypogonadism in mice immunosuppressed with anti-CD4 monoclonal antibody. Exp. Brain Res. 85, 149-152 (1991).
29. Saitoh, Y., Matsui, Y., Nihonmatsu, I. & Kawamura, H. Cross-species transplantation of the suprachiasmatic nuclei from rats to Siberian chipmunks (Eutamias sibiricus) with suprachiasmatic lesions. Neurosci. Lett. 123, 77-81 (1991).
30. Hantraye, P., Riche, D., Maziere, M. & Isacson, O. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl. Acad. Sci. U.S.A. 89, 4187-4191 (1992).
31. Galpem, W.G., Burns, L.H., Deacon, T.W., Dinsmore, J. & Isacson, O. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp. Neurol. 140, 1-13 (1996).
32. Mayer, E., Dunnett, S.B., Pellitteri, R. & Fawcett, J.W. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons-I. Effects in vitro. Neuroscience 56, 379-388 (1993).
33. Nakao, N., et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Med. 1, 226-231 (1995).
34. Lampson, L.A. Molecular bases of the immune response to neural antigens. Trends Neurosci. 10, 211-216 (1987).
35. Neumann, H., Cavalie, A., Jenne, D.E. & Wekerle, H. Induction of MHC class I genes in neurons. Science 269, 549-552 (1995).
36. Pedersen, E.B., Poulson, F.R., Zimmer, J. & Finsen, B. Prevention of mouse-rat xenograft rejection by a combination therapy of cyclosporin A, prednisolone and azathioprine. Exp. Brain Res. 106, 181-186 (1995).
37. Wood, M.J.A, Sloan, D.J., Wood, K.J. & Charlton, H.M. Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. Neuroscience 70, 775-789 (1996).
38. Sachs, D.M. & Bach, F.H. Immunology of xenograft rejection. Hum. Immunol. 28, 245-251 (1990).
39. Steele, D.J. & Auchincloss, H.J. Xenotransplantation. Anna Rev. Med. 46, 345-360 (1995).
40. Hammer, C., Suckfull, M. & Saumweber, D. Evolutionary and immunological aspects of xenotransplantation. Transplant. Proc. 24, 2397-2400 (1992).
41. Public Health Service, H.H.S. Guideline on Infectious Disease Issues in Xenotransplantation. Federal Register 61, 49920-49927 (1996).
42. Ezzeddine, C.D., et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of herpes simplex virus thymidine kinase gene. New Biol. 3, 608-614 (1991).
43. Takamiya, Y., et al. An experimental model of retrovirus gene therapyfor malignant tumours. J. Neurosurg. 79, 104-110 (1993).
44. Oldfield, E.H., Ram, Z., Culver, K.W., Blaese, R.M., DeVroom, H.L. & Anderson, W.F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39-69 (1993).
45. Mabaley, M.S., Jr., Mettlin, C., Natarajan, N., Laws, E.R., Jr. & Peace, B.B. National survey of patterns of care for brain tumor patients. J. Neurosurg. 71, 826-836 (1989).
46. Loeffler, J.S., et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol. 10, 1379-1385 (1992).
47. Miller, A.D. Retrovirus packaging cells. Hum. Gene. Ther. 1, 5-14 (1990).
48. Danos, O. & Mulligan, R.C. Safe and efficient generation of recombinant retrovirus with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85, 6460-6464 (1988).
49. Elion, G.B. The biochemistry and mechanism of action of acyclovir. J. Antimicr. Chemother. 12, 9-17 (1983).
50. Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy. Cancer Res. 56, 5276-5281 (1986).
51. Barba, D., Hardin, J., Sadelain, M. & Gage, F.H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348-4352 (1994).
52. Tapscott, S.J., Miller, A.D., Olson, J.M., Berger, M.S., Croudine, M. & Spence, A.M. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91, 8185-8189 (1994).
53. Kramm, C.M., et al. Gene therapy for brain tumors. Brain Pathol. 5, 345-381 (1995).
54. Naldini, L., Blomer, U., Gage, F.H., Trono, D. & Verma, I.M. Efficient transfer, integration, and long-term sustained expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93, 11382-11388 (1996).
55. Tada, M. & de Tribolet, N. Recent advances in immunobiology of brain tumors. J. NeuroOncol. 17, 261-271 (1993).
56. Michaels, M.G. & Simmons, R.L Xenotransplant-associated zoonoses. Strategies for prevention. Transplantation 57, 1-7 (1994).
57. Ahmed, R., Morrison, L.A. & Knipe, D.M. Persistence of viruses. In fields Virology, Third Ed. (eds. B.N. Fields, D.M.K., P.M. Howley et al.) 221-241 (Lippincott-Raven Publishers, Philadephia, PA, 1996).
58. Coffin, J.M. Retroviridae: the viruses and their replication. In Fields Virology, Third Ed. (eds. B.N. Fields, D.M.K., P.M. Howley et al.) 1767-1847 (Lippincott-Raven Publishers, Philadelphia, PA, 1996).
59. Kawakami, T.G., Sun, L. & McDowell, T.S. Natural transmission of gibbon leukemia virus. J. Natl. Cancer Inst. 61, 1113-1115 (1978).
60. Lieber, M.M., Sherr, C.J., Todaro, G.J., Benveniste, R.E., Callahan, R. & Coon, H.G. Isolation from the asian mouse Mus caroli of an endogenous type C virus related to infectious primate type C viruses. Proc. Natl. Acad. Sci. USA 72, 2315-2319 (1975).
61. Temin, H.M. Reverse transcription in the eukaryotic genome: retroviruses, pararetroviruses, retrotransposons and retrotranscripts. Mol. Biol. Evol. 6, 455-468 (1985).
62. Krieg, A.M. Human Endogenous Retroviruses. Science & Medicine 4, 34-43 (1997).
63. Stoye, J.P., Moroni, C. & Coffin, J. Virological events leading to spontaneous AKR thymomas. J. Virol. 65, 1273-1285 (1991).
64. Vanin, E.F., Kaloss, M., Broscius, C. & Nienhuis, A.W. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J. Virol. 68, 4241-4250 (1994).
65. Kung, H.-J., Boerkoel, C. & Carter, T.H. Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation. Curr. Top. Micro. Immun. 171, 1-25 (1991).
66. Li, J.-P. & Baltimore, D. Mechanism of leukemogenesis induced by mink cell focus-forming murine leukemia viruses. J. Virol. 65, 2408-2414 (1991).
67. Wolff, L. & Ruscetti, S. The spleen focus-forming virus (SFFV) envelope gene, when introduced into mice in the absence of other SFFV genes induces acute erythroleukemia. J. Virol. 62, 2158-2163 (1988).
68. Weller, S.K. & Temin, H.M. Cell killing by avian leukosis viruses. J. Virol. 39, 713-721 (1981).
69. Kristal, B.S., Reinhart, T.A., Hoover, B.A. & Mullins, J.I. Interference with superinfection with cell killing and determination of host range and growth kinetics mediated by feline leukemia virus surface glycoproteins. J. Virol. 67, 4142-4153 (1993).
70. Stoye, J.P., Kenner, S., Greenoats, G.E., Moran, C. & Coff, J.M. Role of endogenous retroviruses as mutagens: the hairless mutation of mice. Cell 54, 383-391 (1988).
71. Barker, D.D., Wu, H., Hartnung, S., M, B. & Jaenish, R. Retrovirus-induced insertional mutagenesis mechanism of collagen mutation in Mov13 mice. Mol. Cell. Biol. 11, 5154-5163 (1991).
72. Lynch, W.P., Czub, S., McAtee, J., Hayes, S.F. & Portis, J.L. Murine retrovirus-induced spongi-form encephalopathy: productive infection of microglia and cerebellar neurons in accelerated CNS disease. Neuron 7, 365-379 (1991).
73. Wiley, C.A. & Gardner, M. The pathogenesis of murine retroviral infection of the central nervous system. Brain Pattol. 3, 123-128 (1993).
74. Cann, A.J. & Chen, I.S.Y. Human T-cell leukemia virus types I and II. In Fields Virology, 3 Ed. (eds. Fields, B.N., Knipe, D.M. & Howley, P.M.) 1849-1880 (Lippincott-Raven Publishers, Philadelphia, PA, 1996).
75. Aziz, D.C., Hanna, Z. & Jolicoeur, P. Severe immunodeficiency disease induced by a defective murine leukaemia virus. Nature 338, 505-508 (1989).
76. Mullins, J.I., Chen, C.S. & Hoover, E.A. Disease-specific and tissue-specific prodcution of unintegrated feline leukemia virus variant DNA in feline AIDS. Nature 319, 333-336 (1986).
77. Rother, R.P., et al. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody. J. Exp. Med. 182, 1345-1355 (1995).